SecBot SecBot
6-K ·Filed Aug 7, 2026

PPBT

PURPLE BIOTECH LTD.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001213900-26-086393
Notable filing: 6-K
Actionable Insight • Neutral

The filing shows continued cash burn and reliance on ATM dilution for funding. With only $6.1M cash and no near-term revenue catalyst, the company will likely need additional financing within 12 months. Preclinical data for IM1240 is early-stage and does not change the fundamental cash runway concern. Monitor for partnership announcements or further equity raises.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.43
T+0 close · Aug 7, 2026 · via day close
Latest settled
−14.69%
T+60 · $1.22
Vs SPY
−12.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 7 $1.43entry
  2. T+1 · 3mo ago +4.90%α +4.92% · $1.50
  3. T+5 · 3mo ago +4.90%α +4.50% · $1.50
  4. T+20 · 2mo ago +22.38%α +22.77% · $1.75
  5. T+60 · 15d ago −14.69%α −12.55% · $1.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Purple Biotech reported Q2 2026 financial results with a net income of $0.4M driven by non-cash warrant revaluation gains, while operating loss widened to $1.3M. Cash and equivalents stood at $6.1M, providing runway through mid-2027 per management. Preclinical data for lead candidate IM1240 was presented at EACR 2026, supporting its safety and pharmacokinetic profile, but the program remains pre-clinical with clinical entry targeted for 2027. The company raised $2.3M gross via an ATM program during H1 2026, adding dilution.

Key Facts

  • Cash and cash equivalents + short-term deposits totaled $6.1M as of June 30, 2026, down from $9.6M at Dec 31, 2025.
  • Net cash used in operating activities was $5.6M for H1 2026 vs $3.5M in H1 2025.
  • Operating loss for Q2 2026 was $1.3M, up from $1.2M in Q2 2025.
  • Net income of $0.4M in Q2 2026 was entirely due to a $1.7M non-cash gain from warrant revaluation.
  • Adjusted net loss (ex-warrant revaluation and stock comp) was $1.2M in Q2 2026 vs $1.1M in Q2 2025.
  • Issued 692k ADS under ATM program in H1 2026, raising $2.3M gross ($2.0M net).
  • IM1240 tri-specific antibody preclinical data presented at EACR 2026; clinical studies targeted for 2027.
  • Accumulated loss reached $170.7M; total equity was $12.2M.
  • Warrant liability fell from $4.1M at Dec 31, 2025 to $0.2M at June 30, 2026 due to revaluation.
  • Company has no revenue and relies on financing for operations.

Financial Impact

Cash burn rate of ~$1.0M/month (operating cash outflow $5.6M over 6 months); $6.1M cash provides ~12 months runway at current burn. Dilution from ATM: 692k ADS issued, representing ~43% of opening ADS count (930k).

cashdilutionoperating lossnet income (non-cash driven)

Risk Factors

  • Cash runway only through mid-2027; may require dilutive financing before then.
  • No approved products or revenue; clinical development of IM1240 is years away from potential commercialization.
  • Significant dilution from ATM program (692k ADS in H1 2026 vs 930k opening balance).
  • Geopolitical risk from Israel operations amid regional conflict.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-086393
Document: ea030094001ex99-1.htm0001213900-26-086393
Document: ea0300940-6k_purple.htm0001213900-26-086393
Document: 0001213900-26-086393-index-headers.html0001213900-26-086393
Document: 0001213900-26-086393-index.html0001213900-26-086393
Document: 0001213900-26-086393.txt0001213900-26-086393

Track record

14 reports on PPBT

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
  2. Nov 12, 20265d ago EFFECT Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $1.49 Now $1.68 +12.75% settles Feb 9
  4. Oct 29, 202618d ago Press Release Neutral 3/10 Entry $1.09 Now $1.68 +54.13% settles Jan 27
  5. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $1.47 Now $1.68 +14.29% settles Dec 31
  6. Sep 9, 20269w ago 6-K Neutral 2/10 Entry $1.74 Now $1.68 −3.45% settles Dec 4
  7. Sep 2, 202610w ago 6-K Neutral 3/10 Entry $1.98 Now $1.68 −15.15% settles Nov 27
  8. Aug 10, 202614w ago 6-K Neutral 4/10 Entry $1.55 to $1.22 Now $1.68 +8.39% ▼ −21.61% −21.13% vs SPY
  9. Aug 7, 202614w ago 6-K Neutral 4/10 Viewing Entry $1.43 to $1.22 Now $1.68 +17.48% ▼ −14.69% −12.55% vs SPY
  10. May 15, 202626w ago Press Release Neutral 4/10 Entry $3.94 to $1.55 Now $1.68 −57.36% ▼ −60.66% −65.18% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 7, 2026